Protalix BioTherapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$0.02 | -$0.02 | -$0.02 |
| Q2 2024 | 1 | $0.02 | $0.02 | $0.02 |
| Q3 2024 | 1 | $0.06 | $0.06 | $0.06 |
| Q4 2024 | 1 | $0.08 | $0.08 | $0.08 |
Protalix BioTherapeutics, Inc. Earnings Date And Information
Protalix BioTherapeutics, Inc. last posted its earnings results on Thursday, November 14th, 2024. The company reported $0.03 earnings per share for the quarter, missing analysts' consensus estimates of $0.06 by $0.03. The company had revenue of 17.96 M for the quarter and had revenue of 65.49 M for the year. Protalix BioTherapeutics, Inc. has generated $0 earnings per share over the last year ($0.1 diluted earnings per share) and currently has a price-to-earnings ratio of -12.94. Protalix BioTherapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 13th, 2025 based on prior year's report dates.
Protalix BioTherapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/14/2024 | Q3 2024 | $0.06 | $0.04 | -0.02 | $16.26 M | $17.96 M |
| 08/14/2024 | Q2 2024 | -$0.01 | -$0.03 | -0.02 | $12.50 M | $13.47 M |
| 05/10/2024 | Q1 2024 | -$0.02 | -$0.06 | -0.04 | $3.75 M | |
| 03/14/2024 | Q4 2023 | -$0.03 | -$0.08 | -0.05 | $10.49 M | |
| 11/06/2023 | Q3 2023 | -$0.07 | -$0.03 | 0.04 | $7.65 M | $10.35 M |
| 08/07/2023 | Q2 2023 | $0.03 | $0.29 | 0.26 | $10.20 M | $35.08 M |
| 05/04/2023 | Q1 2023 | -$0.15 | -$0.05 | 0.1 | $9.59 M | |
| 05/01/2023 | Q4 2022 | -$0.07 | $8.62 M | |||
| 11/14/2022 | Q3 2022 | -$0.15 | -$0.08 | 0.07 | $5.70 M | $14.18 M |
| 08/15/2022 | Q2 2022 | -$0.18 | -$0.11 | 0.07 | $2.68 M | $8.75 M |
| 05/16/2022 | Q1 2022 | -$0.11 | -$0.06 | 0.05 | $16.09 M | |
| 03/31/2022 | Q4 2021 | -$0.15 | $8.55 M | |||
| 11/15/2021 | Q3 2021 | -$0.12 | -$0.09 | 0.03 | $6.90 M | $12.05 M |
| 08/16/2021 | Q2 2021 | -$0.08 | -$0.25 | -0.17 | $8.30 M | $6.43 M |
| 05/14/2021 | Q1 2021 | -$0.17 | -$0.14 | 0.03 | $11.32 M | |
| 03/30/2021 | Q4 2020 | $0.01 | $19.50 M | |||
| 10/29/2020 | Q3 2020 | -$0.08 | -$0.14 | -0.06 | $13.56 M | $10.79 M |
| 08/10/2020 | Q2 2020 | -$0.21 | -$0.13 | 0.08 | $10.87 M | $10.97 M |
| 06/01/2020 | Q1 2020 | -$0.30 | $0.10 | 0.4 | $21.65 M | |
| 03/12/2020 | Q4 2019 | -$0.25 | $0.02 | 0.27 | $17.76 M |
Protalix BioTherapeutics, Inc. Earnings: Frequently Asked Questions
-
When is Protalix BioTherapeutics, Inc.'s earnings date?
Protalix BioTherapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 13th, 2025 based off last year's report dates.
-
How can I listen to Protalix BioTherapeutics, Inc.'s earnings conference call?
The conference call for Protalix BioTherapeutics, Inc.'s latest earnings report can be listened to online.
-
How can I read Protalix BioTherapeutics, Inc.'s conference call transcript?
The conference call transcript for Protalix BioTherapeutics, Inc.'s latest earnings report can be read online.
-
How much revenue does Protalix BioTherapeutics, Inc. generate each year?
Protalix BioTherapeutics, Inc. (:PLX) has a recorded annual revenue of $65.49 M.
-
How much profit does Protalix BioTherapeutics, Inc. generate each year?
Protalix BioTherapeutics, Inc. (:PLX) has a recorded net income of $65.49 M. Protalix BioTherapeutics, Inc. has generated $0.12 earnings per share over the last four quarters.
-
What is Protalix BioTherapeutics, Inc.'s price-to-earnings ratio?
Protalix BioTherapeutics, Inc. (:PLX) has a price-to-earnings ratio of -12.94 and price/earnings-to-growth ratio is -0.37.
